# A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

> **NCT07160400** · PHASE1 · RECRUITING · sponsor: **Innovent Biologics Technology Limited (Shanghai R&D Center)** · enrollment: 104 (estimated)

## Conditions studied

- Part A: Healthy Part B: Overweight or Obesity

## Interventions

- **DRUG:** Placebo
- **DRUG:** IBI3032 tablets

## Key facts

- **NCT ID:** NCT07160400
- **Lead sponsor:** Innovent Biologics Technology Limited (Shanghai R&D Center)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-04
- **Primary completion:** 2026-05-29
- **Final completion:** 2026-09-30
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07160400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07160400, "A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT07160400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*